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 Table 1: Demographic and baseline participant characteristics of patients 
 




Age (years) 62 (52-70) 62 (53-71) 
















Ethnicity: Hispanic/Latino 34 (13ꞏ6) 34 (13ꞏ7) 
Baseline variables 
Tobacco use 50 (20ꞏ0) 39 (15ꞏ7) 
Cocaine use 11 (4ꞏ4) 9 (3ꞏ6) 
Anticoagulated 24 (9ꞏ6) 10 (4ꞏ0) 
Hormone replacement therapy 1 (0ꞏ4) 3 (1ꞏ2) 
Hyperlipidaemia medication compliant 96 (38ꞏ4) 93 (37ꞏ4) 
On antiplatelets 67 (26ꞏ8) 77 (30ꞏ9) 
Diabetes 72 (28ꞏ8) 67 (26ꞏ9) 
Hypertension 241 (96ꞏ4) 240 (96ꞏ4) 
Other cardiovascular disease 38 (15ꞏ2) 34 (13ꞏ7) 












Presentation NIHSS score 19 (15-23) 19 (15-23) 
Diagnostic CT (at presentation) 
ICH volume (mL)  







Stability CT (prior to randomisation) 
ICH volume (mL)  







Ventilation at randomisation 107 (42ꞏ8) 102 (41.0) 
Blood pressure at presentation 
Systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
 
177 (155-208) 
99 (85-113)  
 
176 (158-200) 
98 (84-114)  
Blood pressure at randomisation 
Systolic BP (mm Hg) 







Ictus to diagnostic CT (h) 2ꞏ2 (1ꞏ1-6ꞏ0) 1ꞏ9 (1ꞏ2-4ꞏ8) 
Ictus to stability CT (h) 36ꞏ4 (23ꞏ4-52ꞏ6) 36ꞏ3 (23ꞏ6-48ꞏ6) 
Clot location: deep 163 (65ꞏ2) 144 (57ꞏ8) 










Data are median (IQR) or n (%). Five patients in the MISTIE group and two patients in the 
control group were randomly assigned in error and thus were excluded. GCS=Glasgow Coma 
Scale. NIHSS=National Institutes of Health Stroke Scale. ICH=intracerebral haemorrhage. 
IVH=intraventricular haemorrhage. BP=blood pressure. mRS=modified Rankin Scale. 
*GCS scores range from 15 (fully conscious) to 3 (deep coma). 








Ictus to randomisation (h) 47 (33-60) 46 (36-58) 0ꞏ817 
Ictus to end of treatment (EOT) (h)* 126ꞏ7 (107ꞏ5-150ꞏ7) 122ꞏ7 (112ꞏ9-134ꞏ5) <0ꞏ001 
MISTIE procedure duration (h) 1 (1-1) NA NA 
Number of doses  4 (2-6) NA NA 
EOT CT 
ICH volume (mL) 










EOT ICH remaining ≤15 mL  148 (59ꞏ7) 2 (0ꞏ8) <0ꞏ001 
Withdrawal of care 26 (10ꞏ4) 35 (14ꞏ1) 0ꞏ213 
Days in ICU 12 (7-18) 10 (6-18) 0ꞏ052 
Days to return home 55 (34-105) 62 (35-100) 0ꞏ846 
ICP monitored 
% subjects with any ICP ≥20 mm Hg 
% subjects with any CPP <70 mm Hg 
% ICP readings ≥20 mm Hg† 
















One or more ICP therapies 25/34 (73ꞏ5%) 26/38 (68ꞏ4%) 0ꞏ634 
 
 
Data are median (IQR), mean (SD), or n/N (%). NA=not applicable. ICH=intracerebral haemorrhage. 
IVH=intraventricular haemorrhage. ICU=intensive care unit. ICP=intracranial pressure. CPP=cerebral 
perfusion pressure. *End of treatment time calculated as 24 h after last dose for patients in the MISTIE 
group who received alteplase and as the sum of randomisation time plus median surgical end of 
treatment time for patients in the standard medical care group. This achieved a virtual dosing endpoint 
without alteplase dosing for each individual patient in the standard medical care groups. †Adjusted for 
number of readings per patient. ‡Data were available for 240 patients in the MISTIE group and 238 
patients in the standard medical care group. Additional outcome variable data are included in the 
appendix.  
 Table 3: Safety outcomes 
 







Died within 7 days  10% 2 (0ꞏ8%) 10 (4ꞏ0%) 0ꞏ018 
Died within 30 days  60% 24 (9ꞏ4%) 37 (14ꞏ7%) 0ꞏ066 
Bacterial brain infection within 30 days 15% 2 (0ꞏ8%) 0 (0ꞏ0%) 0ꞏ160 
Symptomatic brain bleeds within 72 h after last dose* NA 6 (2ꞏ4%) 3 (1ꞏ2%) 0ꞏ325 
Asymptomatic brain bleeds within 72 h after last dose* NA 81 (31ꞏ8%) 21 (8ꞏ4%) <0ꞏ001 
Patients with 1 or more serious adverse event within 30 days NA 126 (20ꞏ5%) 142 (26ꞏ9%) 0ꞏ012 
 
Data are n, or n (%). NA=not applicable. *For patients in the MISTIE group who achieved the endpoint before 
alteplase dosing and for patients in the standard medical care group, this was calculated as the corresponding 
median time from randomisation. Safety analyses were done for the full randomised cohort (n=506), including 








































Figure 1: Trial profile 
*All randomly assigned patients (n=506) were included in safety analyses and sensitivity analyses. 
Loss to follow-up occurred when the patient could not be contacted. Withdrawal occurred when 
the patient or family refused to complete the planned follow-up. †Patients were randomly assigned 




assessed for eligibility 
19436 screen failures: 
19206 inclusion criteria not met 
162 refused consent 
68 stability protocol failed 
506 randomised 
255 assigned 
MISTIE 251 assigned standard medical care 
240 included in 
intention-to-treat analysis 
249 included in  
intention-to-treat analysis 
5 ineligible*: 
2 ICH <30 mL 
1 vascular aetiology  
1 clinically improved 
1 withdrew consent 
2 ineligible*: 
1 ICH <30 mL 
1 vascular aetiology 
249 eligible†: 
240 to day 365 
5 lost to follow-up 
4 withdrew 
250 eligible†: 
249 to day 365 
1 lost to follow-up 




Modified Rankin Scale (mRS) at day 365




Extended Glasgow Outcome Scale (eGOS) at day 365
40 50 60 
Proportion of participants (%)
40 50 60
Upper GR Lower MDUpper MD Upper SD Lower SD VS
Figure 2: Independently adjudicated functional outcomes at 365 days 
post ictus for all MISTIE-treated and medical subjects
mRS scores range from 0 (no disability) to 6 (death); eGOS scores range from 8 (upper good recovery) to 1 (death). GR=good 
recovery. MD=moderate disability. SD=severe disability. VS=vegetative state.
The proportion of 365-day mRS 0–3 was 110 (44.2%) in the MISTIE group vs 100 (41.7%) in the medical group. mRS 4–6 was 139 
(55.8%) in the MISTIE group and 140 (58.3%) in the medical group. mRS scores were missing for 10 out of 499 patients; of the 10, 
6 subjects were lost to follow-up, and 4 refused further participation in the study. 
The proportion of 365-day eGOS 4–8 (upper severe disability through upper good recovery) was 94 (38.5%) in the MISTIE group vs 
84 (35.9%) in the medical group. eGOS scores 1–3 (lower severe disability through death) were 150 (61.5%) in the MISTIE group 
and 150 (64.1%) in the medical group. eGOS scores were missing for 21 out of 499 patients, out of which 11 completed the study 
with no eGOS reported, 6 were lost to follow-up, and 4 refused further participation. See appendix tables 5d and 5e for detailed 























95% CI MISTIE 
95% CI Medical
216 210 204
249 193 187 181




Figure 3: Kaplan-Meier survival estimates from day of randomisation 
to observed day of death with truncation at day 365
Estimated survival probabilities were higher throughout 365 days of follow-up with MISTIE 
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Figure 4: MISTIE subgroup analyses
